Drugmaker Daiichi-Sankyo has been granted permission in the multidistrict litigation over blood pressure drug Benicar to hire plaintiffs’ prescribing physicians as experts or consultants for the defense. But a federal judge in New Jersey drew the line at the company’s proposal to set restrictions on prescribing doctors’ ex parte communications with plaintiffs and their attorneys.
Daiichi-Sankyo said in court papers that it sought approval for the measures as a way to prevent plaintiffs counsel from “woodshedding”—manipulating their clients’ doctors’ recollection of events and tainting their eventual testimony.
